Generated November 9, 2026 at 8:31 PM ET
· Covers November 9 trading day
· 10 of 383 ready 8-Ks selected
· AI-assisted overview
The day's highest-materiality 8-K was from The Children's Place, which filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the District of New Jersey and is seeking a Section 363 sale of substantially all assets, including IP, with bids due Dec. 9, 2026. CKX Lands disclosed a $1B investment from Brad Jacobs' Jacobs Private Equity II and co-investors that would give JPE a majority stake, with Jacobs slated to become chairman and CEO and a $20.8M dividend declared. Goodyear named director Roger Wood interim CEO and president after Mark Stewart stepped down immediately, with the board beginning a search and a strategic review continuing. The remaining cards were a mix of M&A and regulatory items, including Corvus Capital's non-binding $2.00-per-share proposal for CDT Equity, Park Dental's completed $39.1M Village Family Dental acquisition, and updates from Netcapital, Larimar Therapeutics and Aldeyra. Earnings filings came from AAON, which reported Q3 sales growth alongside restated first-half results and a disclosed material weakness, and SHF Holdings, which reported a quarterly net loss and going-concern doubt.
GT
GOODYEAR TIRE & RUBBER CO /OH/
leadership
negative
materiality 0.80
November 9, 2026, 7:32 AM ET
Goodyear names director Roger Wood interim CEO as Mark Stewart exits immediately; strategic review continues
- Roger Wood, 64, a director since July 25, 2023 and former Tenneco co-CEO and Dana CEO, was appointed interim CEO and president effective Nov. 8, 2026; board began search for permanent successor.
- Mark Stewart stepped down as CEO, president and director effective immediately; his separation is 'other than for Cause' under Goodyear's Executive Severance and Change in Control Plan.
- Wood will receive $310,000 per month plus monthly RSUs valued at $1,000,000 for the lesser of five months or until a permanent CEO is hired.
regulatory
negative
materiality 0.70
November 9, 2026, 7:30 AM ET
Netcapital receives Nasdaq exception; must file delinquent 10-K and 10-Q by Feb 9, 2027
- Nasdaq granted the exception on Nov. 5, 2026 after reviewing Netcapital's submissions dated Oct. 22 and Oct. 23, 2026.
- Delinquent reports are the FY2026 Form 10-K for the year ended April 30, 2026 and the Form 10-Q for the quarter ended July 31, 2026.
- Nasdaq issued delinquency notices on Aug. 24, 2026 and Sept. 21, 2026 for noncompliance with Listing Rule 5250(c)(1).
M&A
positive
materiality 0.95
November 9, 2026, 6:19 AM ET
Brad Jacobs' JPE to invest $1B in CKX Lands; Jacobs to become chairman and CEO, $20.8M dividend declared
- $900M from Jacobs Private Equity II and $100M from co-investors led by HRTG Partners (formerly Sequoia Heritage); JPE to hold a majority stake.
- Investors get voting convertible perpetual preferred for ~219M shares at $4.57 (pre-split $1.09) plus warrants on ~219M more at $4.57 (50%), $6.85 (25%) and $13.70 (25%).
- Post-close JPE and co-investors would own ~99.78% of common stock on a fully convertible basis, before warrant exercise.
LRMR
Larimar Therapeutics, Inc.
regulatory
positive
materiality 0.80
November 9, 2026, 4:08 PM ET
Larimar completes rolling BLA for nomlabofusp in Friedreich's ataxia; cash $128.7M
- Rolling Biologics License Application submitted to FDA seeking accelerated approval of nomlabofusp, a frataxin replacement therapy, for Friedreich's ataxia.
- BLA relies on skin frataxin as a potential novel surrogate endpoint; FDA previously confirmed the data package appears capable of supporting submission and review.
- Preliminary cash, cash equivalents and marketable securities of ~$128.7M as of Sept 30, 2026; quarter-end close still ongoing and figure unaudited.
M&A
positive
materiality 0.78
November 9, 2026, 8:00 AM ET
Ex-CEO Regan's Corvus proposes to buy CDT Equity at $2.00/share, a 96.3% premium
- Dr. Andrew Regan, CDT's former CEO, delivered a Nov. 5, 2026 letter stating Corvus Capital intends to propose acquiring all outstanding CDT common stock at $2.00/share.
- The $2.00 price is a 96.3% premium, on a post-split basis, to CDT's Nov. 4, 2026 closing price; the proposal is non-binding and no definitive terms have been received.
- Board plans a special committee of independent directors with full authority to consider, negotiate and vote on the proposal and any other strategic alternatives.
PARK
Park Dental Partners, Inc.
M&A
positive
materiality 0.72
November 9, 2026, 4:05 PM ET
Park Dental completes $39.1M Village Family Dental DSO acquisition, expands into North Carolina
- Base consideration of about $39.1M includes 474,535 restricted shares valued at roughly $9.2M, with the remainder in cash subject to working-capital and other adjustments.
- Aggregate consideration may reach about $46.0M via up to $4.6M EBITDA-based and $2.3M employment-contingent payments; seller costs reimbursed up to $823k.
- Adds 12 practice locations and 47 doctors in North Carolina, Park Dental's fourth state alongside Minnesota, Arizona and Wisconsin.
ALDX
Aldeyra Therapeutics, Inc.
regulatory
negative
materiality 0.60
November 9, 2026, 4:02 PM ET
Aldeyra seeks FDA transfer of ADX-2191 PVRL review, withdraws SPA protocol
- Aldeyra asked FDA's Division of Ophthalmology to submit a jurisdiction request to OND to move the ADX-2191 IND for PVRL to the Division of Hematologic Malignancies 2.
- Company notified FDA it withdrew the Special Protocol Assessment protocol for ADX-2191 in PVRL that the Division of Ophthalmology had reviewed and agreed to.
- Aldeyra does not expect to initiate the SPA-contemplated trial while the request is pending and expects the PVRL program will need to be redesigned.
PLCE
Childrens Place, Inc.
other material
negative
materiality 1.00
November 9, 2026, 8:00 AM ET
Children's Place files Chapter 11, seeks Section 363 asset sale by end-December; bids due Dec. 9
- Voluntary chapter 11 petitions filed Nov. 8, 2026 in U.S. Bankruptcy Court for the District of New Jersey, Case No. 26-22682 (SLM); stores and e-commerce remain open.
- Seeks Section 363 sale of substantially all assets, including IP, with bids due Dec. 9, 2026 and sale completion targeted by end of December 2026; in talks with multiple parties.
- About $394M of debt in default and accelerated: Wells Fargo credit facility, SLR/Crystal term loan and Mithaq subordinated notes; automatic stay blocks enforcement.
earnings
positive
materiality 0.90
November 9, 2026, 4:09 PM ET
AAON Q3 sales up 84.1% to $707.4M, EPS $0.83; restates H1 2026, discloses material weakness, raises FY26 outlook
- Q3 net sales record $707.4M, +84.1% YoY; BASX-branded sales $397.2M (+218.3%), AAON-branded $310.2M (+19.6%).
- Operating income $100.0M (+129.3%); GAAP and adjusted diluted EPS $0.83 (+124.3%); gross margin 26.7% vs 27.8% a year ago, up 60 bps sequentially.
- Restated Q1/Q2 2026: Q1 net income cut $3.4M to $36.5M; H1 net income raised $7.1M to $103.6M; first-half sales +$10.7M, diluted EPS +$0.09.
earnings
negative
materiality 0.85
November 9, 2026, 8:15 AM ET
Safe Harbor Q3 revenue $1.95M, net loss $979K; going-concern doubt, Nasdaq extension to April 2027
- Q3 revenue $1.95M (+6.5% YoY); loan program income $869K (+70.2%) as PCCU revenue share rose from ~35% to up to 65%, effective Oct 1, 2025.
- Net loss $979K ($0.95/share) vs year-ago net income $180K, which included a $3.34M debt-extinguishment gain; operating loss narrowed 17.7% to $1.0M.
- Going concern: cash $4.4M vs $6.78M at Dec 31, 2025; $4.05M operating cash burn in 9M 2026; no secured debt; equity line frozen while Opifex term sheet is in effect.